Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India.

Pujari SN, Patel AK, Naik E, Patel KK, Dravid A, Patel JK, Mane AA, Bhagat S.

J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1566-9.

PMID:
15577409
2.

Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.

Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L; Médecins Sans Frontieres.

AIDS. 2006 May 12;20(8):1163-9.

PMID:
16691068
3.

Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon.

Bourgeois A, Laurent C, Mougnutou R, Nkoué N, Lactuock B, Ciaffi L, Liégeois F, Andrieux-Meyer I, Zekeng L, Calmy A, Mpoudi-Ngolé E, Delaporte E.

Antivir Ther. 2005;10(2):335-41.

PMID:
15865228
4.

Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.

Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A.

Antivir Ther. 2005;10(5):605-14.

PMID:
16152754
5.

Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.

van Oosterhout JJ, Kumwenda JJ, Beadsworth M, Mateyu G, Longwe T, Burger DM, Zijlstra EE.

Antivir Ther. 2007;12(4):515-21.

PMID:
17668560
6.

Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program.

Idigbe EO, Adewole TA, Eisen G, Kanki P, Odunukwe NN, Onwujekwe DI, Audu RA, Araoyinbo ID, Onyewuche JI, Salu OB, Adedoyin JA, Musa AZ.

J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):65-9.

PMID:
16123684
8.

Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India.

Kumarasamy N, Vallabhaneni S, Cecelia AJ, Yepthomi T, Balakrishnan P, Saghayam S, Flanigan TP, Carpenter CC, Solomon S, Mayer KH.

J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):53-8.

PMID:
16340473
9.

Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.

Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.

Clin Infect Dis. 2008 Feb 15;46(4):611-21. doi: 10.1086/526780.

PMID:
18197758
10.

Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.

Plana M, Ferrer E, Martínez C, Podzamczer D, García F, Maleno MJ, Barceló JJ, García A, Barberá MJ, Lacarcel M, Miró JM, Gallart T, Gatell JM.

Antivir Ther. 2004 Apr;9(2):197-204.

PMID:
15134181
11.
12.

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.

Martínez E, Blanco JL, Arnaiz JA, Pérez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, García-Viejo MA, Mallolas J, Carné X, Phillips A, Gatell JM.

AIDS. 2001 Jul 6;15(10):1261-8.

PMID:
11426070
13.

Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.

Getahun A, Tansuphasawadikul S, Desakorn V, Dhitavat J, Pitisuttithum P.

J Med Assoc Thai. 2006 Sep;89(9):1472-8.

PMID:
17100387
14.

The long-term effectiveness of generic adult fixed-dose combination antiretroviral therapy for HIV-infected Ugandan children.

Barlow-Mosha LN, Bagenda DS, Mudiope PK, Mubiru MC, Butler LM, Fowler MG, Musoke PM.

Afr Health Sci. 2012 Sep;12(3):249-58.

15.

Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand.

Tsuchiya N, Pathipvanich P, Yasuda T, Mukoyama Y, Rojanawiwat A, Matsubayashi T, Saeng-aroon S, Auwanit W, Matsuyama A, Sawanpanyalert P, Ariyoshi K.

Southeast Asian J Trop Med Public Health. 2009 Jan;40(1):71-82.

PMID:
19323037
16.

Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.

Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, Castelnuovo B, Schaefer P, Spacek LA, Gasasira AF, Katabira E, Colebunders R, Quinn TC, Ronald A, Thomas DL, Kekitiinwa A; Academic Alliance for AIDS Care and Prevention in Africa.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):187-93.

PMID:
17693883
17.

Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.

Reliquet V, Ferré V, Hascoet C, Besnier JM, Bellein V, Arvieux C, Molina JM, Breux JP, Zucman D, Rozenbaum W, Allavena C, Raffi F; VIRGO Study Team.

Antivir Ther. 1999;4 Suppl 3:83-4.

PMID:
16021876
18.

Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.

Smith DE, Chan DJ, Maruszak H, Jeganathan S.

Int J STD AIDS. 2011 Apr;22(4):228-30. doi: 10.1258/ijsa.2010.010258.

PMID:
21515757
19.
20.

Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients.

Kiertiburanakul S, Khongnorasat S, Rattanasiri S, Sungkanuparph S.

J Med Assoc Thai. 2007 Feb;90(2):237-43.

PMID:
17375626

Supplemental Content

Support Center